PTS Diagnostics Expands Leadership Team

PTS Diagnostics Expands Leadership Team

Strategic hires emphasize operations, international sales, research and development

Indianapolis, IN– July 2, 2014- PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand analyzers and the A1CNow® family of point-of-care diagnostic products, announced today it has significantly increased its leadership team with the addition of four strategic new hires. These individuals will immediately impact operations, international sales, and research and development.

The company has tapped the following individuals to continue to drive its rapid global expansion:
• James Anderson, MD – Medical Director
• Keith Moskowitz, PhD, MPM – Vice President, Technology & Development
• John Hurrell, PhD – Senior Vice President, International Sales
• Mark Morgan – Chief Financial Officer and Human Resources Officer

“The addition of these highly-acclaimed, ground-breaking professionals represents a significant step as we expand our product lines and global reach,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “Our company continues to grow. Demand is strong for both our CardioChek analyzers and our A1CNow monitoring systems. These new leaders join a proven and experienced senior management team. Together with our expansive distribution network, PTS Diagnostics will continue to expand and serve more healthcare screening companies, physician offices, healthcare organizations, and labs.”

Dr. Anderson is a physician with over 35 years of experience in metabolic research and pharmaceutical medicine. He was formerly Senior Medical Director for Diabetes and Cardiometabolic Medicine at Eli Lilly and Company. Dr. Anderson’s fellowships include the American College of Endocrinology and the faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians (UK). Dr. Anderson will provide clinical oversight as the company reaches new customers.

Dr. Moskowitz brings 30 years of diagnostic and medical device research and development experience to PTS Diagnostics. His resume boasts a dozen FDA and internationally cleared diagnostics, devices, and controls, as well as over 40 patent applications, publications, and published abstracts. Dr. Moskowitz received a bachelor’s degree in Biochemistry from Rutgers University and a PhD in Biochemistry from Temple University School of Medicine. He is recognized as a Master Project Manager by the American Academy of Project Management. Dr. Moskowitz will lead PTS Diagnostics’ medical device innovation advancements.

Similarly, Dr. Hurrell is a seasoned healthcare executive with extensive diagnostic accomplishments. He has served as senior Executive Vice President, International Business for Seegene Inc., a molecular diagnostics company located in South Korea. Prior to Seegene, he was President and General Manager of two Quest Diagnostics subsidiaries, and was responsible for growing the overall business of the subsidiaries. He also has held senior leadership positions with Boehringer Mannheim (now Roche Diagnostics), Genzyme, TriPath Imaging, and Inproteo. Dr. Hurrell has a PhD from Melbourne University, Australia, and was a Fulbright Fellow at Massachusetts General Hospital in the Harvard Medical School. He will oversee PTS Diagnostics’ international sales efforts.

Mr. Morgan has more than 25 years of global finance and administration experience in life science and medical devices. He brings expertise in providing strategic leadership and significant experience supporting R&D, Supply Chain, and IT with companies including Pfizer, Bayer and Mylan Pharmaceuticals. Mr. Morgan holds an undergraduate degree in Accounting from Indiana State University and an MBA from Illinois State University. He will oversee all Finance and Accounting functions, as well as Human Resources.

“PTS Diagnostics’ goal is to provide a broad portfolio of world-class point-of-care diagnostic solutions. These new individuals, alongside our existing management team, will ensure our future success,” said Huffstodt.

About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow point-of-care systems.

For more information, visit www.ptsdiagnostics.com or contact Laura Wilkerson at 317-870-5610.

All trademarks used or mentioned in this release are protected by law.

SOURCE: PTS Diagnostics
MKG 001029 Rev.1 3/15

PTS Diagnostics Enhances Distributor Network with Strategic Partnership with Independent Medical Co-Op, Inc. (IMCO)

PTS Diagnostics Enhances Distributor Network with Strategic Partnership with Independent Medical Co-Op, Inc. (IMCO)

Indianapolis, IN– July 9, 2014- PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, announced today that it has signed a marketing, sales, and distribution agreement with Independent Medical Co-Op, Inc. (IMCO), one of the premier associations for independent medical distributors.

IMCO is a cooperative association of over 140 medical supply distributors that serve the physician, hospital, long-term care, home health, EMS, veterinary, industrial, and other markets.

“PTS Diagnostics provides best-in-class, point-of-care lipid, glucose, and A1c monitoring solutions,” said Steve Dennison, IMCO’s Director of Vendor Relations. “Our customers count on us to partner with quality manufacturers, and PTS Diagnostics has a proven track record of delivering fast, accurate, and dependable point-of-care devices.”

Robert Huffstodt, President and CEO of PTS Diagnostics, commented that this new relationship is an important strategic agreement that will further broaden the company’s distribution network, while addressing certain growing market segments.

“We are delighted that IMCO will begin selling our products,” said Huffstodt. “IMCO has a long track record of successfully servicing its many customers. Their network of regional distributors is concentrated in market segments where we hope to grow, and their relationships with physician offices and long-term care facilities will certainly help fuel our short- and long-term growth plans.”

IMCO views the new distribution agreement as a way to bring in-demand products to their customers.

“We are seeing an increased demand from our customers for point-of-care diagnostic devices,” continued Dennison. “PTS Diagnostics has world-class products, and they are growing along with the point-of-care industry. We are proud and pleased to welcome them to our family of vendor partners.”

PTS Diagnostics’ handheld, highly-accurate, fast, and economical diagnostic devices empower the medical community to quickly measure a patient’s HbA1c, lipid profile (cholesterol), and glucose results at the point of care. The CardioChek analyzers have provided fast, point-of-care answers to over 100 million patients and their healthcare professionals worldwide. PTS Diagnostics’ devices include:

  • The CardioChek Plus analyzer addresses the connection between heart attack, stroke, and diabetes by providing on-site lipid panel and glucose screening results in as little as 90 seconds. CardioChek Plus offers simultaneous testing of a lipid profile (total cholesterol, HDL cholesterol, and triglycerides) and glucose, and also calculates LDL, TC/HDL ratio, LDL/HDL ratio, and non-HDL cholesterol.
  • The CardioChek PA analyzer accurately determines lipid profile (total cholesterol, HDL cholesterol, and triglycerides) values in 90 seconds and can deliver a single blood chemistry in as little as 45 seconds.
  • The A1CNow®+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.
  • About IMCO – Since 1981, IMCO was established by partnering with key manufacturing companies and all sizes of distributors throughout North America to unite independent medical distributors. IMCO was designed to keep the independent medical distributor independent through direct relationships and total volume pricing. Its members competitively offer the strength of a national service at the local level.

    About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow point-of-care systems.

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at 317-870-5610.

    All trademarks used or mentioned in this release are protected by law.

    SOURCE: PTS Diagnostics
    MKG001347 Rev.0 03/15

    PTS Diagnostics Introduces A1CNow® SELFCHECK Analyzer

    PTS Diagnostics Introduces A1CNow® SELFCHECK Analyzer

    Medical device provides at-home A1c monitoring in less than 5 minutes

    Indianapolis, IN– Sept. 3, 2014 – Consumers now have the ability to test their A1c from home in less than 5 minutes thanks to PTS Diagnostics’ introduction of the A1CNow SELFCHECK system.

    A1CNow SELFCHECK is a consumer-friendly medical device that provides a fast, easy and accurate at-home testing method for obtaining HbA1c results. In just five minutes, people can get an idea of their 2- to 3-month average blood glucose control.

    A1CNow SELFCHECK is now available for purchase online at www.a1cnowselfcheck.com.

    “The A1CNow SELFCHECK system is an important tool for diabetes management,” said James Anderson, MD, PTS Diagnostics’ medical director. “People with diabetes who desire an at-home monitoring system to measure their A1c between physician office visits now have a simple way to aid their self-management. Consumers can know that the A1CNow SELFCHECK system provides accuracy comparable to a certified laboratory method.1.”

    Robert Huffstodt, President and CEO of PTS Diagnostics, commented that the consumer product is essentially the same as the A1CNow+ system used by medical professionals. “A1CNow systems are trusted by medical professionals across the country,” Huffstodt said. “The A1CNow SELFCHECK system uses a very small blood sample from a simple fingerstick. The system is affordable, fast, easy-to-use, and requires no maintenance.”

    The A1CNow SELFCHECK system comes in a convenient 2-test pack with the items the consumer needs to complete both tests (monitor, test cartridges, fingerstick lancets and blood collectors.)

    “A scientific study has demonstrated that just a 1 percentage point reduction in a patient’s A1c level may reduce their risk of complications by up to 40 percent2,” said Dr. Anderson. “Many doctors would agree that when a person with diabetes regularly monitors their A1c levels, they tend to pay closer attention to their diet and, often times, lower the average glucose level in the blood. By regularly monitoring their A1c, a patient can better manage their diabetes.”

    About PTS Diagnostics – PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products. The company is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim.

    For more information, visit http://www.a1cnowselfcheck.com or contact Tom Wiser at 317-870-5610.

    All trademarks used or mentioned in this release are protected by law.

    1. NGSP Certificate September 1, 2014: ptsdiagnostics.com
    2. Stratton IM, Adler Al, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ. 2000;321:405-412.
    MKG001105 Rev.1 03/15

    PTS Diagnostics Named to Inc. Magazine’s 5000 Fastest Growing Private Companies List for the Fourth Time

    PTS Diagnostics Named to Inc. Magazine’s 5000 Fastest Growing Private Companies List for the Fourth Time

    Indianapolis, IN – September 15, 2014 — PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, has again been named to the Inc. 5000 list of the fastest-growing private companies in America. The Inc.5000 ranking is based on revenue growth over a three-year period. PTS Diagnostics earned its place on the list by growing its revenue by 80 percent from 2010 to 2013.

    For PTS Diagnostics, who appears on the list as Polymer Technology Systems, this is the second consecutive year on the list and the fourth time in its history. PTS Diagnostics is the only Indiana medical device manufacturer that made the list in 2014 and has made the list four or more times.

    “We are especially pleased with this distinction this year,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “Our continued growth is a result of our commitment to manufacture and distribute a broad portfolio of diagnostic solutions for point-of-care healthcare providers. It’s gratifying for all of us to see our growth strategies validated in the marketplace and recognized by the media.”

    PTS Diagnostics is experiencing rapid growth with its solutions that aid healthcare professionals in measuring HbA1c and glucose, and generating lipid (cholesterol) profiles, all at the point of care. “The essence of our mission is to improve health,” continued Huffstodt. “We can now provide fast, easy-to-use, accurate, point-of-care diagnostics for multiple key disease states, including high cholesterol and diabetes. Furthermore, we focus on the relationship with our distributors and customers encompassing our proven technology and point-of-care solutions.”

    “We continue to build on this momentum,” concluded Huffstodt. “We have recently added new distribution partners to further expand our market reach; made key hires for our research, technology, sales, and marketing teams; and we have invested significantly in our manufacturing and quality control areas. We are excited to continue our ongoing commitment to providing a full suite of world-class point-of-care diagnostic solutions to healthcare professionals of all kinds, all around the world.”

    PTS Diagnostics’ portfolio includes the following systems:
  • The CardioChek Plus analyzer addresses the connection between heart attack, stroke, and diabetes by providing simultaneous on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) and glucose screening results in as little as 90 seconds. The CardioChek Plus also calculates LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.
  • The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.
  • About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow systems.

    About Inc. 5000 – The Inc. 500|5000 is a list of the fastest-growing private companies in the nation. Started in 1982, this prestigious list of the nation’s most successful private companies has become the hallmark of entrepreneurial success. The Inc. 5000 profiles are available on Inc.com.

    All trademarks used or mentioned in this release are protected by law.

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at 317-870-5610.

    MKG001115 Rev.1 03/15

    PTS Diagnostics Products Now Distributed by Cardinal Health

    PTS Diagnostics’ Products Now Distributed by Cardinal Health

    Indianapolis, IN – October 6, 2014 – PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, announced today that they have signed a national sales and distribution agreement with Cardinal Health, one of the largest providers of equipment and supplies to the healthcare industry.

    “We are excited to add Cardinal to our distribution network,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “Point-of-care diagnostics is a critical service that is experiencing a large increase in demand from the healthcare industry. PTS Diagnostics’ product line, with its ability to measure Lipids and A1c levels, is a nice fit into the solutions that Cardinal offers to their clients.”

    Huffstodt commented that Cardinal Health would further extend PTS Diagnostics’ reach within healthcare integrated delivery networks (IDNs), including physicians’ offices.

    “As one of the highest volume distributors of healthcare equipment and products, Cardinal Health is a perfect partner for us,” said Huffstodt. “Their client base includes the entire integrated hospital network: physicians’ offices, urgent care, screening locations, and point-of-care sites. This distribution agreement is an opportunity for us to broaden our reach in those areas.”

    PTS Diagnostics’ point-of-care analyzers and systems are a great addition to the physician office setting commented James Anderson, MD, PTS Diagnostics’ Medical Director.

    “The CardioChek analyzers and A1CNow systems are tremendous resources for treating two key disease states: heart disease and diabetes,” said Dr. Anderson. “The efficiency of fast test results and the opportunity for face-to-face patient consultation are valuable enhancements to any patient-care setting.”

    PTS Diagnostics’ handheld, highly-accurate, fast, and economical diagnostic devices empower the medical community to quickly measure HbA1c, glucose, and generate a lipid (cholesterol) profile, all at the point of care. PTS Diagnostics’ portfolio includes the following systems:
  • The CardioChek Plus analyzer addresses the connection between heart attack, stroke, and diabetes by providing simultaneous on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) and glucose screening results in as little as 90 seconds. The CardioChek Plus also calculates LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.
  • The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.
  • “We look forward to a long and successful partnership,” concluded Huffstodt. “We are seeing remarkable growth in our business, and in point-of-care diagnostic opportunities around the world. Cardinal Health, with their far-reaching distribution network and exceptional industry reputation, will be instrumental in our growth plans.”

    About Cardinal Health – Cardinal Health is a Fortune 22 company that improves the cost-effectiveness of healthcare. As the business behind healthcare, Cardinal Health helps pharmacies, hospitals and ambulatory care sites focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability. Cardinal Health employs more than 30,000 people worldwide.

    About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow systems.

    All trademarks used or mentioned in this release are protected by law.

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at 317-870-5610.

    SOURCE: PTS Diagnostics
    MKG001130 Rev. 0 10/14